Cochrane Clinical Answers
Cochrane Clinical Answers (CCAs) provide a readable, digestible, clinically focused entry point to rigorous research from Cochrane systematic reviews. They are designed to be actionable and to inform decision making at the point of care and have been added to relevant sections of the main Best Practice text.
- What are the effects of sodium glucose co‐transporter‐2 (SGLT2), dipeptidyl peptidase‐4 (DPP‐4) inhibitors and glucagon‐like peptide‐1 (GLP‐1) agonists for adults with diabetes and chronic kidney disease (CKD)?
- How does tight glycemic control compare with non-tight control for preventing diabetic kidney disease and its progression?
- In people with diabetic kidney disease, is there randomized controlled trial evidence to support the use of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists to prevent progression?
- What are the effects of lowered dietary salt intake for preventing diabetic kidney disease and its progression?
- In people with diabetic kidney disease, does pentoxifylline improve outcomes?
Use of this content is subject to our disclaimer